Cargando…
Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? – New insights from RIVER trial
Novel oral anticoagulants, with dabigatran in particular have failed in their quest to replace the traditional anticoagulation in the form of vitamin K antagonist in patients with mechanical valvular implants. However, the same had not been tried in bioprosthetic valve recipients until recently in a...
Autores principales: | Sahu, Ankit Kumar, Katheria, Arpita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424354/ https://www.ncbi.nlm.nih.gov/pubmed/34474770 http://dx.doi.org/10.1016/j.ihj.2021.06.019 |
Ejemplares similares
-
Bioprosthetic mitral valve thrombosis
por: Bouwmeester, S., et al.
Publicado: (2022) -
Percutaneous mitral valve repair: the beginning of the end or the end of the beginning?
por: Vahanian, Alec, et al.
Publicado: (2010) -
Left Atrial Thrombus in a Patient with Mitral Bioprosthetic Valve
por: Tas, Muhammed Hakan, et al.
Publicado: (2013) -
NOAC versus warfarin in the treatment of atrial fibrillation during the first three months after bioprosthetic aortic valve replacement
por: Piepiorka-Broniecka, Marta, et al.
Publicado: (2022) -
Acute thrombosis of bioprosthetic mitral valve
por: Kwon, Jin-Tae, et al.
Publicado: (2013)